RU2016148735A - Производные пиразина - Google Patents
Производные пиразина Download PDFInfo
- Publication number
- RU2016148735A RU2016148735A RU2016148735A RU2016148735A RU2016148735A RU 2016148735 A RU2016148735 A RU 2016148735A RU 2016148735 A RU2016148735 A RU 2016148735A RU 2016148735 A RU2016148735 A RU 2016148735A RU 2016148735 A RU2016148735 A RU 2016148735A
- Authority
- RU
- Russia
- Prior art keywords
- group
- pharmaceutically acceptable
- solvate
- acceptable salt
- methyl
- Prior art date
Links
- 150000003216 pyrazines Chemical class 0.000 title claims 19
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- DCYTULXIJQTPEW-UHFFFAOYSA-N 2-(6-cyanopyrazin-2-yl)-3-[(2,5-dichlorophenyl)methyl]-5-methylimidazole-4-carboxylic acid Chemical compound C(#N)C1=CN=CC(=N1)C=1N(C(=C(N=1)C)C(=O)O)CC1=C(C=CC(=C1)Cl)Cl DCYTULXIJQTPEW-UHFFFAOYSA-N 0.000 claims 2
- YQIRMNZWWRIXHU-UHFFFAOYSA-N 2-(6-cyclopropylpyrazin-2-yl)-3-[(2,5-dichlorophenyl)methyl]-5-methylimidazole-4-carboxylic acid Chemical compound C1(CC1)C1=CN=CC(=N1)C=1N(C(=C(N=1)C)C(=O)O)CC1=C(C=CC(=C1)Cl)Cl YQIRMNZWWRIXHU-UHFFFAOYSA-N 0.000 claims 2
- UFAXIQXKXNRNKK-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)methyl]-2-(6-ethoxypyrazin-2-yl)-5-methylimidazole-4-carboxylic acid Chemical compound ClC1=C(CN2C(=NC(=C2C(=O)O)C)C2=NC(=CN=C2)OCC)C=C(C=C1)Cl UFAXIQXKXNRNKK-UHFFFAOYSA-N 0.000 claims 2
- TZATXNVJILUVCE-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)methyl]-2-(6-ethylpyrazin-2-yl)-5-methylimidazole-4-carboxylic acid Chemical compound ClC1=C(CN2C(=NC(=C2C(=O)O)C)C2=NC(=CN=C2)CC)C=C(C=C1)Cl TZATXNVJILUVCE-UHFFFAOYSA-N 0.000 claims 2
- KRBUOYHOAMZQPB-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)methyl]-2-(6-methoxypyrazin-2-yl)-5-methylimidazole-4-carboxylic acid Chemical compound ClC1=C(CN2C(=NC(=C2C(=O)O)C)C2=NC(=CN=C2)OC)C=C(C=C1)Cl KRBUOYHOAMZQPB-UHFFFAOYSA-N 0.000 claims 2
- HMKGBOBTFIOBCI-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)methyl]-5-methyl-2-(6-methylpyrazin-2-yl)imidazole-4-carboxylic acid Chemical compound ClC1=C(CN2C(=NC(=C2C(=O)O)C)C2=NC(=CN=C2)C)C=C(C=C1)Cl HMKGBOBTFIOBCI-UHFFFAOYSA-N 0.000 claims 2
- GQAGKBUYGPOSML-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)methyl]-5-methyl-2-(6-phenoxypyrazin-2-yl)imidazole-4-carboxylic acid Chemical compound ClC1=C(CN2C(=NC(=C2C(=O)O)C)C2=NC(=CN=C2)OC2=CC=CC=C2)C=C(C=C1)Cl GQAGKBUYGPOSML-UHFFFAOYSA-N 0.000 claims 2
- KWPRUZXMSRFIMD-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)methyl]-5-methyl-2-(6-phenylpyrazin-2-yl)imidazole-4-carboxylic acid Chemical compound ClC1=C(CN2C(=NC(=C2C(=O)O)C)C2=NC(=CN=C2)C2=CC=CC=C2)C=C(C=C1)Cl KWPRUZXMSRFIMD-UHFFFAOYSA-N 0.000 claims 2
- SOCRBZIALSDUNY-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)methyl]-5-methyl-2-(6-propan-2-ylpyrazin-2-yl)imidazole-4-carboxylic acid Chemical compound ClC1=C(CN2C(=NC(=C2C(=O)O)C)C2=NC(=CN=C2)C(C)C)C=C(C=C1)Cl SOCRBZIALSDUNY-UHFFFAOYSA-N 0.000 claims 2
- FVWVMNATKMYAFH-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)methyl]-5-methyl-2-pyrazin-2-ylimidazole-4-carboxylic acid Chemical compound ClC1=C(CN2C(=NC(=C2C(=O)O)C)C2=NC=CN=C2)C=C(C=C1)Cl FVWVMNATKMYAFH-UHFFFAOYSA-N 0.000 claims 2
- DDBVXDKQUBUDMO-UHFFFAOYSA-N 3-[(2,5-dichlorothiophen-3-yl)methyl]-5-methyl-2-(6-methylpyrazin-2-yl)imidazole-4-carboxylic acid Chemical compound ClC=1SC(=CC=1CN1C(=NC(=C1C(=O)O)C)C1=NC(=CN=C1)C)Cl DDBVXDKQUBUDMO-UHFFFAOYSA-N 0.000 claims 2
- VFFJZSIWAWTRLZ-UHFFFAOYSA-N 3-[(2,5-dichlorothiophen-3-yl)methyl]-5-methyl-2-pyrazin-2-ylimidazole-4-carboxylic acid Chemical compound ClC=1SC(=CC=1CN1C(=NC(=C1C(=O)O)C)C1=NC=CN=C1)Cl VFFJZSIWAWTRLZ-UHFFFAOYSA-N 0.000 claims 2
- CUFJEDGLCSGVEN-UHFFFAOYSA-N 3-benzyl-2-[6-(2-fluoro-6-methoxyphenoxy)pyrazin-2-yl]-5-methylimidazole-4-carboxylic acid Chemical compound C(C1=CC=CC=C1)N1C(=NC(=C1C(=O)O)C)C1=NC(=CN=C1)OC1=C(C=CC=C1OC)F CUFJEDGLCSGVEN-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- ASUMVAPLXCRBMA-UHFFFAOYSA-N (3,5-dichloro-4-hydroxyphenyl)-(2,3-dihydro-1,4-benzoxazin-4-yl)methanone Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1C(=O)N1C2=CC=CC=C2OCC1 ASUMVAPLXCRBMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006773 (C2-C7) alkylcarbonyl group Chemical group 0.000 claims 1
- OTQIKKBNIWNDHC-UHFFFAOYSA-N 1-[(2,5-dichlorophenyl)methyl]-5-pyrazin-2-ylpyrrole-2-carboxylic acid Chemical compound ClC1=C(CN2C(=CC=C2C(=O)O)C2=NC=CN=C2)C=C(C=C1)Cl OTQIKKBNIWNDHC-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 claims 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 claims 1
- 229940083914 URAT1 inhibitor Drugs 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014-099677 | 2014-05-13 | ||
| JP2014099677 | 2014-05-13 | ||
| PCT/JP2015/063654 WO2015174417A1 (ja) | 2014-05-13 | 2015-05-12 | ピラジン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016148735A3 RU2016148735A3 (enExample) | 2018-06-19 |
| RU2016148735A true RU2016148735A (ru) | 2018-06-19 |
Family
ID=54479954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016148735A RU2016148735A (ru) | 2014-05-13 | 2015-05-12 | Производные пиразина |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9856237B2 (enExample) |
| EP (1) | EP3144306B1 (enExample) |
| JP (1) | JP6173576B2 (enExample) |
| KR (1) | KR20170004998A (enExample) |
| CN (1) | CN106458998A (enExample) |
| AR (1) | AR100403A1 (enExample) |
| AU (1) | AU2015260300A1 (enExample) |
| CA (1) | CA2948797A1 (enExample) |
| CY (1) | CY1119876T1 (enExample) |
| DK (1) | DK3144306T3 (enExample) |
| ES (1) | ES2654434T3 (enExample) |
| HR (1) | HRP20180122T1 (enExample) |
| HU (1) | HUE035728T2 (enExample) |
| IL (1) | IL248900A0 (enExample) |
| LT (1) | LT3144306T (enExample) |
| ME (1) | ME02978B (enExample) |
| MX (1) | MX2016014693A (enExample) |
| NO (1) | NO3144306T3 (enExample) |
| PH (1) | PH12016502223A1 (enExample) |
| PL (1) | PL3144306T3 (enExample) |
| PT (1) | PT3144306T (enExample) |
| RS (1) | RS56837B1 (enExample) |
| RU (1) | RU2016148735A (enExample) |
| SG (1) | SG11201609359WA (enExample) |
| SI (1) | SI3144306T1 (enExample) |
| SM (1) | SMT201800155T1 (enExample) |
| TW (1) | TW201609702A (enExample) |
| WO (1) | WO2015174417A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN116496198A (zh) * | 2023-06-26 | 2023-07-28 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种4-羟基-2'-(1-苄基-5-硝基吡咯甲叉)-苯甲酰肼衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4397875B2 (ja) | 1997-02-05 | 2010-01-13 | 第一三共株式会社 | 糖尿病合併症予防薬又は治療薬 |
| WO1998034922A1 (en) * | 1997-02-05 | 1998-08-13 | Sankyo Company, Limited | Prophylactic or therapeutic agent for diabetic complication |
| CA2511859A1 (en) * | 2003-01-02 | 2004-07-22 | Alexander Mayweg | Novel cb 1 receptor inverse agonists |
| JP2007145786A (ja) | 2005-11-30 | 2007-06-14 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| RU2515968C2 (ru) * | 2007-04-11 | 2014-05-20 | Киссеи Фармасьютикал Ко., Лтд. | 5-членное гетероциклическое соединение и его применение для лекарственных целей |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| MX2015003672A (es) * | 2012-11-14 | 2015-06-15 | Teijin Pharma Ltd | Derivados de piridina. |
-
2015
- 2015-05-12 AR ARP150101453A patent/AR100403A1/es unknown
- 2015-05-12 DK DK15792266.7T patent/DK3144306T3/en active
- 2015-05-12 TW TW104115028A patent/TW201609702A/zh unknown
- 2015-05-12 WO PCT/JP2015/063654 patent/WO2015174417A1/ja not_active Ceased
- 2015-05-12 SG SG11201609359WA patent/SG11201609359WA/en unknown
- 2015-05-12 ME MEP-2018-5A patent/ME02978B/me unknown
- 2015-05-12 RU RU2016148735A patent/RU2016148735A/ru not_active Application Discontinuation
- 2015-05-12 SM SM20180155T patent/SMT201800155T1/it unknown
- 2015-05-12 LT LTEP15792266.7T patent/LT3144306T/lt unknown
- 2015-05-12 JP JP2016519266A patent/JP6173576B2/ja not_active Expired - Fee Related
- 2015-05-12 KR KR1020167031523A patent/KR20170004998A/ko not_active Withdrawn
- 2015-05-12 AU AU2015260300A patent/AU2015260300A1/en not_active Abandoned
- 2015-05-12 MX MX2016014693A patent/MX2016014693A/es unknown
- 2015-05-12 CA CA2948797A patent/CA2948797A1/en not_active Abandoned
- 2015-05-12 PL PL15792266T patent/PL3144306T3/pl unknown
- 2015-05-12 NO NO15792266A patent/NO3144306T3/no unknown
- 2015-05-12 SI SI201530130T patent/SI3144306T1/en unknown
- 2015-05-12 US US15/310,337 patent/US9856237B2/en not_active Expired - Fee Related
- 2015-05-12 CN CN201580024718.7A patent/CN106458998A/zh active Pending
- 2015-05-12 ES ES15792266.7T patent/ES2654434T3/es active Active
- 2015-05-12 EP EP15792266.7A patent/EP3144306B1/en active Active
- 2015-05-12 RS RS20180019A patent/RS56837B1/sr unknown
- 2015-05-12 PT PT157922667T patent/PT3144306T/pt unknown
- 2015-05-12 HR HRP20180122TT patent/HRP20180122T1/hr unknown
- 2015-05-12 HU HUE15792266A patent/HUE035728T2/en unknown
-
2016
- 2016-11-09 PH PH12016502223A patent/PH12016502223A1/en unknown
- 2016-11-10 IL IL248900A patent/IL248900A0/en unknown
-
2018
- 2018-02-01 CY CY20181100126T patent/CY1119876T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015260300A1 (en) | 2016-12-22 |
| TW201609702A (zh) | 2016-03-16 |
| JPWO2015174417A1 (ja) | 2017-04-20 |
| PT3144306T (pt) | 2018-01-08 |
| RU2016148735A3 (enExample) | 2018-06-19 |
| SMT201800155T1 (it) | 2018-05-02 |
| CA2948797A1 (en) | 2015-11-19 |
| MX2016014693A (es) | 2017-02-23 |
| US9856237B2 (en) | 2018-01-02 |
| EP3144306A4 (en) | 2017-03-22 |
| PH12016502223A1 (en) | 2017-02-06 |
| US20170152242A1 (en) | 2017-06-01 |
| KR20170004998A (ko) | 2017-01-11 |
| WO2015174417A1 (ja) | 2015-11-19 |
| HRP20180122T1 (hr) | 2018-02-23 |
| EP3144306A1 (en) | 2017-03-22 |
| ES2654434T3 (es) | 2018-02-13 |
| JP6173576B2 (ja) | 2017-08-02 |
| SI3144306T1 (en) | 2018-02-28 |
| HUE035728T2 (en) | 2018-05-28 |
| IL248900A0 (en) | 2017-01-31 |
| RS56837B1 (sr) | 2018-04-30 |
| DK3144306T3 (en) | 2018-01-02 |
| SG11201609359WA (en) | 2016-12-29 |
| PL3144306T3 (pl) | 2018-04-30 |
| EP3144306B1 (en) | 2017-11-15 |
| NO3144306T3 (enExample) | 2018-04-14 |
| CN106458998A (zh) | 2017-02-22 |
| ME02978B (me) | 2018-10-20 |
| CY1119876T1 (el) | 2018-06-27 |
| AR100403A1 (es) | 2016-10-05 |
| LT3144306T (lt) | 2018-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501250A5 (enExample) | ||
| EP3990448A4 (en) | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | |
| RU2011143741A (ru) | Производное индолизина и его применение в медицинских целях | |
| RU2015123499A (ru) | Соединения замещенной триазолбороновой кислоты | |
| GEP201606507B (en) | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors | |
| JP2017528524A5 (enExample) | ||
| SMT201300098B (it) | Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide | |
| JP2016531121A5 (enExample) | ||
| MX380928B (es) | Inhibidores de kras g12c. | |
| RU2535347C3 (ru) | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний | |
| JP2017502940A5 (enExample) | ||
| AR074426A1 (es) | Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende | |
| TW201613568A (en) | Pharmaceutical composition comprising novel hydroxamic acid derivative or salt thereof | |
| DK1599450T3 (da) | Fremgangsmåde til fremstilling af 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydtroxy-(1H)-quinolin-2-on-salte, der kan anvendes som adrenoceptor-agonister | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| JP2016531126A5 (enExample) | ||
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| RU2016120610A (ru) | Производное сульфонамида и его применение в медицине | |
| JP2016528273A5 (enExample) | ||
| JP2015500842A5 (enExample) | ||
| RU2016104844A (ru) | Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора | |
| EA201270099A1 (ru) | Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота | |
| RU2016142611A (ru) | Пролекарственные средства ингибиторов обратной транскриптазы вич | |
| CL2020002550A1 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos. | |
| JP2015524843A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20181112 |